Proteome Sciences Share Discussion Threads

[chutes01] 05/3/2021 14:57

Lockdown has not been good for many people, the effects will become apparent to the wider society over the coming months.

[tom barnaby] 05/3/2021 14:52

I note that avatars have drained, topped up and drained again Peters infamous goblet of insanity today.

[bluemango] 05/3/2021 14:07

'An on-demand company presentation will be available beginning at 7:00am ET on March 9, 2021'

More on CT1812:

[bluemango] 05/3/2021 14:05

#58441 Background info - Shareholders will recall the phosphorylation of tau being a specific area of PRM expertise, in research work involving Ck1d.

[wasjobber] 05/3/2021 14:04

Yes, but what's significant about 9th March Cognition announcement?

[bluemango] 05/3/2021 14:03

PRM known to be working with Cognition Therapeutics on Alzheimer's, eg from this release mentioning CT1812:

[monte1] 05/3/2021 13:56

This is just like the good olde days again. The Richards talking to himself about a lot of not very much at all.

[wasjobber] 05/3/2021 13:53

xtrader,

And you think 9th March will benefit Proteome Sciences ???

[1xtrader] 05/3/2021 13:30

9 March I think they mentioned

[1xtrader] 05/3/2021 13:30

https://www.google.co.uk/amp/s/cogrx.com/cognition-therapeutics-to-present-corporate-and-clinical-update-at-h-c-wainwright-global-life-sciences-conference/%3famp

[elpirata] 05/3/2021 13:26

placing reliance on a 9 year old work of fiction is probably not the way to go 1xtrader






if you ask pools2 nicely, he might lend you goatherds calculator

[1xtrader] 05/3/2021 13:22

Ct1812 that's all I'm going to say

[elpirata] 05/3/2021 13:20

#Value !!!

[1xtrader] 05/3/2021 13:19

Proof is in the pudding we will see the true valuation when it is or if it is sold and you can split hairs over it

[1xtrader] 05/3/2021 13:15

WevalueProteomeSciences at£127mbasedonasum-of-the-partsDCFvaluation.There is potential uncertainty about the company's revenue growth, driven largely by a need to see pharmaceuticalcompanies usingProteomeSciences toconduct proteinassays andthe company's limitedabilitytodateto achievesignificant monetisationofits IP portfolio.So our valuationincludes a 75% risk-adjustment onrevenues (although they are in line with company guidance); if this risk-adjustmentis removed,ourvaluationincreases to£153m.There ispotentiallysubstantialadditionalupsidefromaspectsofthecompany'sIPportfolio,such as its CK1? AD drug discovery programme,which is not included in our valuation.Sensitivities: Ability to commercialise IP portfolioT h e b u s i n e s s m o d e l a r o u n d b i o m a r k e r c o n t r a c t r e s e a r c h i s n e w a n d t h e r e m a y b e s o m e r e s i s t a n ce frompharmaceuticalcompaniesinitiallytothismodel.AlthoughProteomeSciences'CRO offering hasarelativelyshorttrackrecordithasaunique serviceoffering basedonitsproprietaryisobaric masstaggingandbiomarkers.Similarly,additionaldata demonstratingtheability of its biomarkers todiagnoseaccuratelyadiseaseisrequiredforthem tobeout-licensedandusedwidely.Financials: Revenue growth forecast to accelerate in FY12We forecast that revenues will increase by 239% in FY12 to £3.2m and in FY13 by 109% to £6.7m, in line with company guidance, as Proteome Sciences benefits from the launch of c 50 biomarkers in assays overthelastyearandincreases its marketingactivities.Thestrongrevenuegrowthis forecasttomakethecompanyprofitableandcashgenerativefromFY14, asitscostbasehas remainedstableoverrecent yearsanditisonly expectedtoincreaseat5%painthecomingyears.ProteomeSciences had a cashpositionof c £4.4m at FY11; this should be sufficient to reach break-even, assuming that its debt is not called in and its future clients settletheir invoices in 90 days onaverage

[elpirata] 05/3/2021 13:12

oh dear

well lets take a leap of faith and say sales increase by 30% this year to £6m

GP runs at a consistent 55% which is £3.3m

Admin post redundancies etc is circa £3m giving pbt of £300,000

295,000,000 shares in issue so eps before tax 0.001p per share

4p/5p

what do you think revenues will be for 2021?

[1xtrader] 05/3/2021 13:09

Thats what I thought avoid the question change the subject because you haven't got the balls to answer the question

[elpirata] 05/3/2021 13:05

is everything alright at home 1xtrader?

[1xtrader] 05/3/2021 13:03

Ok enlighten me If your so smart, you ask me my opinion then you me tell it's not an opinion what side the bed did you get out off today

[elpirata] 05/3/2021 13:00

thats not really a calculation is it 1xtrader?

prm sales last year were £4.6m

what do you think revenues will be for 2021?

[1xtrader] 05/3/2021 12:58

elpirataHow about you what's your value

[1xtrader] 05/3/2021 12:54

Well lots to factor in,forward earnings and take into consideration of the Edison 2012 report is one way but 12 million at it's current value is a steal for the likes of multi billion pound company, there are many pharmaceutical companies valued ten times proteome sciences and not making a penny, and don't have many projects but my gut feeling is minimum £60 million up to £200 million

[elpirata] 05/3/2021 12:45

I suspect monte1 might have peeked at the share price which corresponds with the value the market places on prm

and your calculation 1xtrader?